Wellgistics Health (WGRX) maps vertical integration and blockchain-focused healthcare push
Wellgistics Health (WGRX) has detailed a new strategic direction focused on vertically integrated, blockchain-based healthcare infrastructure. This strategy involves connecting data, verification, and patient engagement through its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system, leveraging recent acquisitions and partnerships like DelivMeds AI, QOLPOM, and Tollo Health. The company aims to own the data, verification, and patient relationship across the prescription journey, with upcoming milestones including a share restructuring and the August 2026 launch of the Health Lives Here app.
MAY 21·Stock Titan→
From drones to data: how Wellgistics plans to reshape pharmacy care
Wellgistics Health (NASDAQ: WGRX) has released a letter to shareholders detailing its strategic vision for vertical integration and blockchain adoption in healthcare. The company plans to integrate its EinsteinRx AI dispensing platform into PharmacyChain, acquire the QOLPOM patent portfolio for biometric verification and drone delivery, and obtain a controlling interest in Tollo Health and Forzet to directly engage patients, particularly those on GLP-1 medications. This strategy aims to create a unified data fabric across the healthcare industry, addressing fragmentation and inefficiency.
MAY 20·Datavault AI▲
Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health
Datavault AI Inc. and Wellgistics Health are forming DelivMeds AI through a series of strategic transactions with an estimated combined asset value of $4 billion. This new entity will expand Wellgistics' PharmacyChain™ license to include Healthcare-as-a-Service (HaaS) IP, acquire QOLPOM biometric health data and drone logistics IP, and take a controlling stake in Tollo Health. DelivMeds AI aims to integrate blockchain-enabled healthcare data management, biopharmaceutical delivery, and AI-driven health solutions to improve patient outcomes and compliance, piloting its "Health Lives Here" program in July 2026.
